Journal — Xhealth
Xhealth
JOURNAL / ISSUE 12LONG-READS FROM THE SCIENCE TEAM

Notes from
the lab.

Occasional writing on the papers we read, the diseases we work on, and the questions that decide what we develop next. Dermatology, but taken seriously — as a medical field, not a category of cosmetics.

FEATURE · TRANSDERMAL · FEBRUARY 2026 · 12 MIN READ

The 15-micron problem —
and why we solved it in foam.

Transdermal drug delivery has quietly become the most productive corner of small-molecule pharmacology. The reasons are boring — no first-pass metabolism, no needles, no compliance drop-off — but the pharmacology is beautiful. A short essay on why Xhealth's next decade sits behind the stratum corneum, and what our new permeation-enhancer chassis unlocks for actives that were previously deemed undeliverable.

Read essay →
Transdermal delivery lab
§ ARCHIVE

More reading.

AGA
HAIR HEALTH · FEB 2026 · 4 MIN

Androgenetic alopecia in 2026 — what a Nature primer tells us

Hair loss is one of the most common conditions in medicine — yet for millions of people, it remains undertreated and a source of genuine psychological distress. The 2025 Nature Reviews Disease Primers review of AGA lays out the clearest picture yet: a condition driven by genetic predisposition and androgen signalling through DHT, with minoxidil, finasteride, dutasteride, low-level laser therapy and PRP forming the evidence-graded therapeutic ladder. Xhealth's hair portfolio — Xcare Minoxidil 5% Foam and XGaine Finasteride Scalp Spray — is built directly on this evidence base.

Read →
Melasma
PIGMENT · JAN 2026 · 5 MIN

Melasma is not a stain — it is a disease

The 2025 JAAD global consensus on melasma reframes it as a chronic, relapsing dermatosis of pigmentary dysfunction — not a cosmetic complaint that resolves with a strong cleanser. The pharmacological consequence is clear: hydroquinone monotherapy for maintenance, triple-combination FHT for moderate-to-severe presentations, and long-horizon patient education. Xhealth's Skinoro 2% and Skinoro FHT map precisely onto this clinical ladder.

Read →
Antifungal
FORMULATION · JAN 2026 · 6 MIN

One tube, seven days — the pharmacokinetics of a single-dose antifungal

Athlete's foot is a two-week clinical problem and a two-week compliance problem. J Drugs Dermatol data on single-application film-forming terbinafine shows fungicidal concentrations maintained for 13 days after a single dose — the pharmacology behind Dr Giles ONCE Terbinafine 1% Polymer Gel. A short note on how our polymer chassis holds an antifungal on the foot long after the tube is thrown away.

Read →
Scar remodelling
SCAR · DEC 2025 · 5 MIN

Scars remember — how early topical intervention changes their trajectory

The dermatology literature is unusually clear on scar management: intervene early, hydrate the matrix, modulate inflammation. Onion-extract + heparin + allantoin combinations have RCT-level data across surgical, burn and post-acne populations for reducing hypertrophy and improving pliability. A short overview of the biology, the evidence, and where DeScars® fits into a post-op protocol.

Read →
Topical finasteride
DELIVERY · NOV 2025 · 7 MIN

Topical finasteride, oral finasteride — and what the serum tells us

A 2024 British Journal of Dermatology systematic review compared topical scalp finasteride and its oral counterpart across hair-count endpoints and serum DHT. The finding: comparable scalp efficacy with markedly reduced systemic exposure — a signal we take seriously because side-effect fear is the single biggest reason men stop treatment. XGaine Finasteride 2.275 mg/ml Cutaneous Spray is our answer to that fear.

Read →
MPS polysaccharide
POLYSACCHARIDES · OCT 2025 · 8 MIN

Fifty years of MPS — the quietest workhorse in topical medicine

Mucopolysaccharide polysulfate has been used clinically since the 1960s. It never became famous, but it kept being effective. A long look at what MPS actually does at the dermal level — how it holds water, how it stimulates the skin's own hyaluronate, and why laser-Doppler studies keep showing it can reach vessel-level tissue despite its molecular weight. The pharmacological backbone of Hirudiox®.

Read →
Benzoyl peroxide acne
ACNE · SEP 2025 · 4 MIN

Benzoyl peroxide, still — the case for resistance-neutral acne care

Topical antibiotics for acne carry a resistance debt the field has been paying for two decades. Benzoyl peroxide, by contrast, kills C. acnes oxidatively and provokes no resistance. The 2024 EADV guidelines now recommend BPO as the backbone of mild-to-moderate acne, ideally combined with topical retinoids. A note on why we still ship a 5% BPO gel — and why we won't stop.

Read →
SUBSCRIBE · 6 ISSUES / YEAR · NO SPAM

Monthly reading list
from the science team.